AURINIA PHARMACEUTICALS INC

AUPH NASDAQ

CryptoFundManager

AURINIA PHARMACEUTICALS INC - TRIAL DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT AND SUSPENDS DEVELOPMENT PROGRAM FOR VOCLOSPORIN OPHTHALMIC SOLUTION! With a 1.732B MARKET CAP and a Net Income (FY) of -126.725M, the stock seems overvalued and needs a correction. The indicators signal: Sell on 1h timeframe Sell on 7h timeframe Sell on daily...

Trade4158

AUPH finally has a green buy signal ! Set up is perfect.

Trade4158

We've signaled that $15 breakout was coming...it has happened and maybe FDA approval is on way soon!

Barker

Buyout potential on this one.

Trade4158

AUPH spent the summer as a bummer for all who bought the secondary at $15, but fall conferences ( OPCO on SEPT 23) will get the bystanders in this jewel which should eventually be bought out.

Barker

A close today anywhere near 14.75 would virtually guarantee it. Target 18.40

torquio

AUPH is sitting on fib support here. Great spot to buy. Expecting this one to double.

TopMarketGainers

Looks like a perfect ABCDE correction is about to breakout. Short term targets as per chart.

keifer

Hello, What is AUPH? Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. News Last week Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that it completed a regulatory submission to the FDA seeking approval for its drug, voclosporin. If successful,...

fhenry0331

Low highs, lower lows. Expecting drop

DanBrooks123

If pattern breaks down short term run looks good to $18.30

Capitalist-Pig

www.fool.com Expecting this stock to pull back but the motley fool gives long advice.

Barker

Long from 16

SysionUS

AUPH to hold for greater gains in the near future. See comments on chart for more information. No BUY or SELL targets.

Bullishcharts

Entry level $8.00 = Target price $9.75 = Stop loss $7.50 Possible long term breakout in the stock which has made a nice recovery on the back of earnings surprise. It's possible it may consolidate for a few days on the market weakness. Average analysts price target $13 | BUY rating High 14% short interest Company profile Aurinia Pharmaceuticals, Inc. operates as...

daytraderrockstar

Phase 3 Trial News about to be released within 2 weeks, most likely first week of December

nobituus

TREND CONTINUOUS, STOP AND TP AS INDICATED

AlenCiken

- Low dose voclosporin achieves CR rate of 49.4% at 48 weeks (p<.001) - AURORA Phase III trial with low dose voclosporin on track to commence in Q2 2017 ir.auriniapharma.com seekingalpha.com